Sildenafil, a phosphodiesterase 5 inhibitor, is currently under investigation for therapy of pulmonary hypertension. This study was designed to investigate chronic effects of sildenafil in monocrotaline (MCT)-induced pulmonary hypertension in rats. Four weeks after a single subcutaneous injection of MCT, the animals displayed nearly threefold elevated pulmonary artery pressure and vascular resistance values, with a concomitant decline in central venous oxygen saturation and arterial oxygenation. Marked right heart hypertrophy was evident, and massive thickening of the precapillary artery smooth muscle layer was histologically apparent. Further deterioration of pulmonary hypertension occurred 6 weeks after MCT injection, with some animals dying during this period because of right heart failure. When chronically administered from Days 14-28, sildenafil significantly increased plasma cyclic guanosine monophosphate and inhibited the development of pulmonary hypertension and right heart hypertrophy, with preservation of gas exchange and systemic arterial pressure. A corresponding efficacy profile was also noted for long-term feeding with sildenafil from Days 28-42. Moreover, the death rate significantly decreased in those animals treated with sildenafil. We conclude that sildenafil attenuates MCT-induced pulmonary hypertension and cor pulmonale in rats.
Pulmonary arterial hypertension is a fatal disease, often affecting young people (1, 2) . It is characterized by intimal lesions, medial hypertrophy, and adventitial thickening of precapillary pulmonary arteries. Because of the severe increase in afterload, right ventricular hypertrophy and right heart failure develop. Increased vasomotor tone and chronic remodeling of the precapillary resistance vessels, including marked vascular smooth muscle cell growth, are assumed to be underlying pathogenetic mechanisms.
Recent short-term studies in patients suffering from pulmonary hypertension suggest that the phosphodiesterase (PDE) 5 inhibitor sildenafil is an effective pulmonary vasodilator (3) (4) (5) (6) (7) (8) (9) (10) . This agent has been approved for erectile dysfunction, possesses excellent availability after oral intake, and has undergone extensive toxicologic testing (11, 12) . PDEs hydrolyze second messengers of the pulmonary vasodilator agents prostacyclin and nitric oxide, namely cAMP and cyclic guanosine monophosphate (cGMP) (13) . Recent studies showed that the cGMP-specific PDE5 is highly expressed in lung tissue (14, 15) . Moreover, further upregulation of PDE5 may occur under conditions of pulmonary hy-(Received in original form February 26, 2003 ; accepted in final form September 3, 2003) Supported by the Deutsche Forschungsgemeinschaft (SFB 547, Project C6).
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Beyond acute pulmonary vasodilation, PDE inhibitors may also possess antiremodeling potency via increased cAMP and cGMP levels (19) , thus offering the possibility of beneficial longterm administration. In this study, we addressed this issue in a model of chronic pulmonary hypertension, employing the alkaloid monocrotaline (MCT). This toxin from plants of the Crotalaria species (20) causes pulmonary arterial endothelial cell injury and subsequent pulmonary artery smooth muscle hypertrophy with persistent severe pulmonary hypertension after one injection in rats (21) . We investigated the chronic efficacy of oral sildenafil in this model and particularly addressed the question of whether long-term daily intake of sildenafil (1) during development of pulmonary hypertension and (2) after full establishment of MCTinduced pulmonary hypertension might exert beneficial effects on lung vascular remodeling, right heart hypertrophy, and survival. Some of the results of these studies have been previously reported in the form of an abstract (22) .
METHODS

MCT Treatment
MCT (Sigma, Deishofen, Germany) was dissolved in 0.5 N of HCl, and the pH was adjusted to 7.4 with 0.5 N of NaOH. The solution was given as a single subcutaneous injection (60 mg/kg) to male Sprague Dawley rats. Control rats received an equal volume of isotonic saline.
Surgical Preparation and Tissue Preparation
The animals were initially anesthetized with intraperitoneal pentobarbital and were ventilated with 10 ml/kg body weight and a frequency of 60 s Ϫ1 (SAR830A/P; IITC, Woodland Hills, CA) after tracheostomy. The Fi O 2 was set at 0.5, and a positive end-expiratory pressure of 1.5 cm H 2 O was used throughout. Anesthesia was maintained by inhalation of isoflurane.
Hemodynamic Measurements
A right heart catheter (PE 50 tubing) was inserted through the right jugular vein for measurement of right ventricular pressure, and the left arteria carotis was cannulated for arterial pressure monitoring. Cardiac output was measured by thermodilution technique (Cardiotherm 500-X; Hugo-Sachs Electronic-Harvard Apparatus GmbH, March-Hugstetten, Germany). Briefly, a thermistor catheter (1.5ЊF) was forwarded into the ascending thoracic aorta via the right carotid artery for the measurement of transpulmonary thermodilution cardiac output. A 0.15-ml bolus of room-temperature saline was injected into the right ventricle as an indicator, and cardiac output was averaged from three consecutive determinations and indexed to the weight of the animal to obtain the cardiac index. After exsanguinations, the left lung was fixed for histology in 10% neutral-buffered formalin, and the right lung was frozen in nitrogen.
Measurement of Organ Weight
The heart was dissected, and the ratio of the right ventricle to left ventricle plus septum weight (RV/LV ϩ S) was calculated as an index of right ventricular hypertrophy.
Measurement of Plasma cGMP Level
cGMP levels were determined using a radioimmunoassay (Immunotech, Marseille, France), as described (23) . The cGMP concentrations in plasma were expressed as pmol per ml.
Western Blot Assay
Frozen lung tissues were homogenized and centrifuged at 13,000 rpm for 30 minutes. The supernatants were measured for protein content using Dye Reagent Concentrate (Bio-Rad, Munich, Germany). Extracts containing equal amounts of protein (10 g for matrix metalloproteinase [MMP-2] and 30 g for MMP-9) were denatured and separated on 7.5% sodium dodecyl sulfate polyacrylamide gels. The separated proteins were blotted on a polyvinylidene fluoride membrane with a semidry transfer unit at 100 mA for 2 hours. The blots were blocked and developed with 0.3 and 0.2 g/ml of rabbit polyclonal IgG antibodies for specific rat MMP-2 and MMP-9 and a 1/7,500 dilution of horseradish peroxidase-labeled goat anti-rabbit IgG (Abcam Ltd., Cambridge, UK). The bands were visualized using an enhanced chemiluminescence detection system (Amersham Corp., Arlington Heights) and quantified by densitometry.
Paraffin Embedding and Microscopy
Fixation was performed by immersion of the lungs in a 3% paraformaldehyde solution. For paraffin embedding, whole lung was dissected in tissue blocks from all lobes. Sectioning at 10 m was performed from all paraffin-embedded blocks. Hematoxylin and eosin elastica staining was performed according to common histopathologic procedures. Light microscopic slides were analyzed in a blind fashion without the knowledge of treatment groups. In each rat, 40 to 50 intraacinar arteries were categorized as muscular (i.e., with a complete medial coat of muscle), partially muscular (i.e., with only a crescent of muscle), or nonmuscular (i.e., no apparent muscle), as reported (24) . Microscopy and photography were performed with a Nikon UFX-II microscope with a Nikon D1 attached to the phototube at a magnification of ϫ100-ϫ400.
Experimental Protocols
For chronic studies, rats were randomized to receive either placebo of sildenafil in the drinking water. Six groups were studied: control 28 
Data Analysis
All data are given as means Ϯ SEM. Differences between groups were assessed by the use of analysis of variance and the Student-NewmanKeuls post hoc test for multiple comparisons, with a p value of less 
11.28
Definition of abbreviations: CI ϭ cardiac index; control ϭ control animals (n ϭ 8); F value ϭ value of F distribution; MCT 28 ϭ monocrotaline-treated animals for 28 days (n ϭ 10); MCT 42 ϭ monocrotaline-treated animals for 42 days (n ϭ 10); MCT 28 /Sil 14-28 ϭ 100 g/kg day sildenafil from Day 14 to Day 28 (n ϭ 8); MCT 42 /Sil 28-42 ϭ 100 g/kg day sildenafil from Day 28 to Day 42 (n ϭ 8); PVRI ϭ pulmonary vascular resistance index; RV/LV ϩ S ϭ ratio of right to left ventricle plus septum; RVP ϭ right ventricular pressure; SAP ϭ mean systemic arterial pressure; Sv O Figure  3) . Moreover, the body weight was lower than that of the timematched control animals. All rats of the control groups survived for the entire experimental period (n ϭ 8 each). The survival rate of the MCT 28 treated animals, a significant increase in plasma cGMP levels occurred under sildenafil treatment: from 13.8 Ϯ 2.1 to 34.7 Ϯ 3.1 pmol/ml at Day 28 (p Ͻ 0.05) and from 16.5 Ϯ 1.6 to 42.6 Ϯ 2.9 pmol/ml at Day 42 (p Ͻ 0.05). This was accompanied by a decrease in MMP-2 and MMP-9 protein content for both enzymes (Figure 7 ).
DISCUSSION
The pyrrolizidine alkaloid MCT is used experimentally to cause pulmonary hypertension in rats. The proposed mechanism of action includes activation of MCT by the liver to the putative electrophile MCT pyrrole (20, 21, 25) , which causes endothelial injury in the pulmonary vasculature with subsequent remodeling of the precapillary vessels (medial thickening, de novo muscularization of small pulmonary arterioles). Because of this mimicry of clinical pulmonary arterial hypertension, the rat MCT model has repeatedly been employed for investigating acute hemodynamic and gas exchange effects of vasodilators and chronic antiremodeling effects of antiinflammatory and antiproliferative agents (26) (27) (28) (29) . Reproducible induction of severe, progressive pulmonary hypertension in response to MCT was also achieved in this study. Both pulmonary vascular resistance and pulmonary artery pressure increased approximately threefold, accompanied by a significant decrease in arterial and venous oxygenation and some (nonsignificant) reduction of cardiac index. In line with these findings, an impressive right heart hypertrophy, obvious from the weight ratio of right to left ventricle plus septum, was observed. This was accompanied by a weight loss of the animals because of the severity of the disease. Some animals died most probably because of right heart failure before reaching the end of the experimental protocol. Remodeling of precapillary resistance vessels is evident histologically by the marked media hypertrophy in these vessels and by quantitative morphometric analysis.
For chronic sildenafil treatment, we started the therapeutic intervention when the development of pulmonary hypertension had already commenced, from Week 2 to Week 4, which is in contrast to most previous investigations in this model, in which the MCT and the agent of interest were coapplied (e.g., endothelin-antagonist [28] , prostaglandin E 1 [29] , or E4010 [30] ). In spite of delayed administration, significant attenuation of pulmonary hypertension evolving in response to the pyrrolizidine was noted. This was obvious from the lower values of systolic pulmonary artery pressure and pulmonary vascular resistance obtained on catheterization of these animals as well as the extent of right heart hypertrophy. Concomitantly, arterial oxygenation improved, accompanied by an increase in central venous oxygen saturation, although the cardiac index did not substantially increase. It has to be kept in mind that these measurements addressed only baseline hemodynamics. As known from patients with pulmonary hypertension, a decrease in pulmonary vascular resistance may allow one to respond more adequately with cardiac index increase to exercise, even if baseline cardiac index is unchanged (31, 32) . Moreover, better coping with pulmonary hypertensive crises might be expected. Thus, although baseline cardiac index did not change in response to sildenafil treatment, the significant reduction of pulmonary vascular resistance index may translate into a survival benefit in these animals, as being observed. The systemic arterial pressure was fully maintained. The extent of the pulmonary vascular resistance decrease after 2 weeks of sildenafil treatment and the profile of changes (no systemic arterial pressure decline) strongly suggest that beyond its acute vasodilatory efficacy the PDE5 inhibitor exerted an antiremodeling effect in the pulmonary circulation of the MCT- Figure 6 . Effect of sildenafil on the degree of muscularization of peripheral pulmonary arteries. Percentage of nonmuscularized (nm), partially muscularized (pm), or fully (m) muscularized pulmonary arteries related to the total number of pulmonary arteries. A total of 40 to 50 intraacinar vessels were analyzed in each lung from rats exposed to MCT for 28 treated animals. This view is also supported by the histologic demonstration of reduced medial thickening of the precapillary lung arteries under sildenafil and the significant reduction of fully muscularized peripheral pulmonary arteries. This phenomenon has been described most recently in hypoxia-induced pulmonary hypertension in rats (33) . These findings are of interest as two independent studies, which investigated long-term inhalation of nitric oxide in MCT-treated rats, did not observe beneficial effects under these conditions (34, 35) . Thus, the sildenafil mode of action appears to exceed the efficacy of nitric oxide in this model, which may be due to the fact that this PDE5 inhibitor also amplifies nitric oxide-independent cGMP-linked effects, such as those forwarded by natriuretic peptides. Moreover, crossstabilization of cAMP or cyclic nucleotide unrelated effects of sildenafil might be involved. It is of interest that markedly enhanced cGMP levels were demonstrated in MCT-treated rats fed with E4010, another PDE5 inhibitor, although no hemodynamic measurements were undertaken in this previous study (30) . We found similar levels of plasma cGMP under basal conditions and MCT treatment, and it is of interest that under sildenafil treatment we did not reach such high levels as in E4010-treated rats but similar effects on mortality and right heart hypertrophy, even when therapy was started after the development of pulmonary hypertension.
Clear efficacy of sildenafil was also demonstrated when this agent was employed as "rescue" therapy from Days 28-42, after a 4-week period of full establishment of MCT-induced pulmonary hypertension. A significant inhibition of progression (right ventricular systolic pressure, RV/LV ϩ S) was noted. After 42 days, the pulmonary vascular resistance values of the sildenafil-treated animals were below those of the MCT 42 control animals and below those of the MCT 28 control subjects. Moreover, survival of the MCT 42 /Sil [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] rats surpassed that of the MCT 42 animals. This observation is in line with the previous report that the PDE5 inhibitor E4010 reduced mortality of MCT-treated rats when coadministered with the alkaloid (30) .
Finally, the gelatinases MMP-2 and MMP-9 were found to be downregulated in the sildenafil-treated groups. These matrix metalloproteinases are linked to proliferation and migration of vascular cells, and it has been shown recently that both MMPs are downregulated in response to the stable cGMP analogue 8-bromo-cGMP or the nitric oxide-donor NONOate (36) . These findings further support the view that sildenafil exerts a substantial antiproliferative effect in the MCT model. When performing long-term feeding with sildenafil, the development of vascular remodeling and right heart hypertrophy in response to MCT was attenuated, with preservation of gas exchange and systemic arterial pressure. Further efficacy was demonstrated when this PDE5 inhibitor was employed for late therapeutic intervention after full establishment of the pulmonary vascular abnormalities. Although these studies were undertaken in an experimental model, which may not be predictive of response to therapy in humans, the results suggest that sildenafil may be useful for antiremodeling therapy in patients with pulmonary hypertension.
